The agent was given to patients prior to chemotherapy...The drug is in Phase II studies in refractory pediatric patients. * IDEC Pharmaceuticals Corp., of San Diego, is getting $1.5 million for expanding its marketing collaboration for IDEC-C2B8, a potential B cell lymphoma drug, with Genentech Inc., of South San Francisco, to include Japan and other Asian countries

The award was created by philanthropist Teresa Heinz to celebrate the power of the individual in America. * Endogen Inc., of Cambridge, Mass., expanded its supply and marketing agreement with Amersham International plc, of Buckinghamshire, England, to include human cytokine test kits...It is the first retinoid or vitamin A derivative to be indicated for cancer in the U.S. * Immunex Corp., of Seattle, is presenting papers at the American Society of Hematology conference, in Seattle, that showed

Adcon (short for adhesion control) is a semisynthetic carbohydrate polymeric gel. * Human Genome Sciences Inc., of Rockville, Md., said its chairman and CEO, William Haseltine, was a co- recipient with former First Lady Nancy Reagan of an annual award from the New York-based Carter Burden Foundation for the Aging for contributions to understanding health problems of older people. * Interneuron Pharmaceuticals Inc., of Lexington, Mass., signed an agreement with Ingelheim, Germany-based

BioStar Inc., of Boulder, Colo., received FDA clearance to market its Optical ImmunoAssay chlamydia point-of- care test...Metra Biosystems Inc., of Mountain View, Calif., and Wyeth-Ayerst Laboratories, of Radnor, Pa., initiated a non-exclusive worldwide co-promotion collaboration related to the company's products to diagnose, treat and prevent osteoporosis...Initially, the plan is to increase education and awareness of bone disorders. (c) 1997 American Health Consultants

The trial will involve 10 to 20 ALS patients and six healthy volunteers, all of whom will receive 28 days of treatment. * Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported positive data from a Phase I/II study of its anti- multidrug resistance compound, VX-710, in combination with the anti-cancer drug, doxorubicin...VX-710 is designed to prevent tumor cells' multidrug resistance gene from pumping out chemotherapeutics before they have a chance to work

The product is used to restore dermal tissue in burn patients. * Lidak Pharmaceuticals Inc., of La Jolla, Calif., raised $9 million in the first stage of a planned $15 million financing...VX-710 is designed to prevent tumor cells' multidrug resistance gene from pumping out chemotherapeutics before they have a chance to work

In addition to determining a maximum dose toleration for the drug, the trials will assess anti-tumor activity...Genta expects to file an investigational new drug application with the FDA next year to begin clinical studies in the U.S. * Lidak Pharmaceuticals Inc., of La Jolla, Calif., raised $9 million in the first stage of a planned $15 million financing

By inhibiting a complement response, the drug is designed to prevent the unleashing of cell- destroying enzymes, which when produced in excess can cause dangerous inflammation associated with such disorders as cardiac reperfusion, transplant rejection and respiratory ailments...Phase II trials of TP10 are expected to begin in 1996 for adult respiratory distress syndrome. * Lidak Pharmaceuticals Inc., of La Jolla, Calif., raised $9 million in the first stage of a planned $15 million financing...The

Phase II trials of the vaccine are expected to begin in 1996 in cystic fibrosis and chronic bronchitis patients. * Corvas International Inc., of San Diego, said preclinical studies of its thrombin inhibitor, which is derived from proteins produced by blood-feeding hookworms (ancylostoma caninum), showed the compound was effective and safe as an anti-blood- clotting drug...The buy-out is valued at between $12.50 to $13 per share...Phase II trials of TP10 are expected to begin in 1996 for adult

The drug is designed to bind to the CD2 receptor on the surface of immune system T cells. * Carrington Laboratories Inc., of Irving, Texas, signed an agreement with Mexico-based Laboratorios PiSA S.A...Phase II trials of TP10 are expected to begin in 1996 for adult respiratory distress syndrome. (c) 1997 American Health Consultants

The new company, which will focus on late-stage development and commercialization of new and formulated products in Asia, is 40 percent owned by Genelabs, 35 percent by the Taiwan government and 25 percent by private investors. (See BioWorld Today, July 18, 1995, p. 1.) * Guilford Pharmaceuticals Inc., of Baltimore, licensed rights to a biodegradable polymer from Yissum Research Development Corp...of the Hebrew University of Jerusalem, which it intends to develop for the delivery of drugs for

The work will broaden the company's gene therapy program for cancer by allowing in vivo administration of genes. * CoCensys Inc., of Irvine, Calif., completed a Phase I trial that showed ACEA 1021, a glycine-site N-Methyl- D-Aspartate receptor antagonist for stroke, was well tolerated and had no side effects. * Neurex Corp., of Menlo Park, Calif., said a Phase I/II study of SNX-111 for severe pain in seven patients showed the agent has potential to provide symptomatic relief in those who had

Serious infections occurred in 5 of 29 (17 percent) of infants given Leukine compared to 12 of 31 (39 percent) in the placebo group. * ImmunoGen Inc., of Cambridge, Mass., hired PaineWebber Inc., of New York, to help it achieve its partnering objectives. * IMRE Corp., of Seattle, said the FDA conditionally approved a 268-patient pivotal trial of its Prosorba column for the treatment of rheumatoid arthritis. * NeXstar Pharmaceuticals Inc., of Boulder, Colo., acquired patent rights to MiKasome

The company is developing non- absorbed, polymer-based drugs that selectively bind to and eliminate substances from the intestinal tract. * Immunex Corp., of Seattle, said it was served with two lawsuits from shareholders in connection with the buyout offer from American Home Products Corp., of Madison, N.J. Among the allegations is that the $14.50-per-share buyout price is too low. (See BioWorld Today, Nov. 3, 1995, p. 1.) * Innovir Laboratories Inc., of New York, entered into a research

The shares were sold to private and institutional investors. * Texas Biotechnology Corp., of Houston, started its second Phase III study of Novastan for heparin-induced thrombocytopenia and thrombosis syndrome...It's a randomized, double-blind 300-patient trial comparing the drug to ancrod, an anti-thrombotic. (c) 1997 American Health Consultants

Guilford will sell Gliadel to Orion and receive milestone and other payments. * InSite Vision Inc., of Alameda, Calif., which is developing eyedrop-based drug delivery technology, is restructuring to conserve cash...Procysteine is designed to replenish glutathione, which protects the body from reactive oxygen species. * Trinity Biotech, of Dublin, Ireland, raised $3 million in an offering to European institutional investors. (c) 1997 American Health Consultants

Rh's parent company, the Apotex Pharmaceutical Group, of Toronto, owns 85 percent of the new company. (See BioWorld Today, Aug. 1, 1995, p. 1.) * IBEX Technologies Inc., of Montreal, said a second Phase I study of Neutralase confirmed its ability to neutralize heparin in humans. * Parexel International Corp., a Boston-based contract research organization, said the Inter-Company Collabo- ration for AIDS Drug Development began its second research study _ one-year trials of 225 HIV patients in

Oncor Inc., of Gaithersburg, Md., said its premarket approval application for the in vitro diagnostic genetic test system for HER-2/neu will be reviewed Nov. 30, 1995, by an FDA advisory panel. * Ostex International Inc., of Seattle, entered into an agreement with SmithKline Beecham Clinical Laboratories, of Philadelphia, to market and sell its Osteomark test, which measures human bone loss, in the U.S. * Glyco Biomedical Ltd., of Novato, Calif., was awarded two grants totaling $127,000, one

felis bacteria is related to Helicobacter pylori, which is believed to be responsible for most peptic ulcers...plc, of Athlone, Ireland, agreed to pay Emisphere Technologies Inc., of Hawthorne, N.Y., $15 million in a joint venture aimed at combining Elan's drug delivery systems with Emisphere's membrane absorption technologies in the development of oral heparin